Nova Eye Medical Stock Performance
| ELXMF Stock | USD 0 0.00 0.00% |
The company secures a Beta (Market Risk) of 1.81, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nova Eye will likely underperform. At this point, Nova Eye Medical has a negative expected return of -1.51%. Please make sure to verify Nova Eye's standard deviation, as well as the relationship between the maximum drawdown and day median price , to decide if Nova Eye Medical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Nova Eye Medical has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's primary indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 17.8 M | |
| Total Cashflows From Investing Activities | -4.5 M | |
| Free Cash Flow | -10.3 M |
Nova |
Nova Eye Relative Risk vs. Return Landscape
If you would invest 10.00 in Nova Eye Medical on September 30, 2025 and sell it today you would lose (9.81) from holding Nova Eye Medical or give up 98.1% of portfolio value over 90 days. Nova Eye Medical is currently producing negative expected returns and takes up 12.1678% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Nova, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Nova Eye Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nova Eye's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Nova Eye Medical, and traders can use it to determine the average amount a Nova Eye's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.124
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ELXMF |
Based on monthly moving average Nova Eye is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nova Eye by adding Nova Eye to a well-diversified portfolio.
Nova Eye Fundamentals Growth
Nova Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Nova Eye, and Nova Eye fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nova Pink Sheet performance.
| Return On Equity | -0.23 | |||
| Return On Asset | -0.15 | |||
| Profit Margin | (0.56) % | |||
| Operating Margin | (0.72) % | |||
| Current Valuation | 25.06 M | |||
| Shares Outstanding | 145.88 M | |||
| Price To Earning | 0.66 X | |||
| Price To Book | 0.92 X | |||
| Price To Sales | 2.18 X | |||
| Revenue | 13.63 M | |||
| EBITDA | (7.89 M) | |||
| Cash And Equivalents | 8 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 1.94 M | |||
| Debt To Equity | 0.06 % | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (4.72 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 36.62 M | |||
About Nova Eye Performance
By analyzing Nova Eye's fundamental ratios, stakeholders can gain valuable insights into Nova Eye's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nova Eye has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nova Eye has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. Nova Eye Medical Limited was founded in 1985 and is headquartered in Kent Town, Australia. Nova Eye operates under Medical Devices classification in the United States and is traded on OTC Exchange.Things to note about Nova Eye Medical performance evaluation
Checking the ongoing alerts about Nova Eye for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Nova Eye Medical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nova Eye Medical generated a negative expected return over the last 90 days | |
| Nova Eye Medical has high historical volatility and very poor performance | |
| Nova Eye Medical has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 13.63 M. Net Loss for the year was (7.5 M) with profit before overhead, payroll, taxes, and interest of 11.09 M. | |
| Nova Eye Medical has accumulated about 8 M in cash with (4.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 21.0% of the company shares are held by company insiders |
- Analyzing Nova Eye's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nova Eye's stock is overvalued or undervalued compared to its peers.
- Examining Nova Eye's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nova Eye's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nova Eye's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nova Eye's pink sheet. These opinions can provide insight into Nova Eye's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Nova Pink Sheet analysis
When running Nova Eye's price analysis, check to measure Nova Eye's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Eye is operating at the current time. Most of Nova Eye's value examination focuses on studying past and present price action to predict the probability of Nova Eye's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Eye's price. Additionally, you may evaluate how the addition of Nova Eye to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |